Vas Narasimhan
@VasNarasimhanReimagining medicine as CEO of @Novartis
Similar User
@jaybradner
@Novartis
@NovartisNews
@bmsnews
@LifeSciVC
@JohnCendpts
@JebKeiper
@BiotechCH
@NovartisUS
@Frank_S_David
@ldtimmerman
@NovartisUSMed
@michael_gilman
@NovartisScience
@JMaraganore
On the latest episode of The @DM_Rubenstein Show: Peer-to-Peer Conversations, I had the chance to speak with David about my career and leadership journey and all I’ve learned along the way. I hope you’ll watch the episode here: youtu.be/t8ifgEIbgvg?si…
Great to talk with @JimCramer yesterday morning about what @Novartis’ renewed strategy has meant for our business performance and the strength of our pipeline of innovative medicines. #JPM24
Novartis is entering its new era as a focused medicines company from a position of strength. Today, I’m proud to share our very strong results for Q3. Read more from @Novartis here: novartis.com/news/media-rel…
Novartis delivered a very strong quarter, with double-digit sales and core operating income growth leading to a further upgrade to 2023 guidance. #NovartisNews $NVS $NOVN #NVSQ323
Today’s announcement is another promising step forward on our journey to reimagine medicine for and with patients around the world.
Novartis announces initial Ph 3 trial results of complement inhibitor in rare kidney disease IgAN #NovartisNews
Our Beacon of Hope summer fellowship students met CEO @VasNarasimhan and had the chance to ask him questions and share their experiences at Novartis labs. We look forward to continuing to support students from Historically Black Medical Schools and break down #DEI barriers.
These trial results bring us one step closer to a potential first-in-class treatment for patients living with CSU. Thank you to all those involved in this study.
Novartis announces REMIX Phase III studies met their primary endpoint in chronic spontaneous urticaria – an unpredictable and debilitating immunological condition. #NovartisNews
Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off. #NovartisNews $NVS $NOVN #NVSQ223
IgA nephropathy is a devastating disease, mostly affecting young adults, that could lead to dialysis or kidney transplantation. We’re excited by the opportunity to address this healthcare challenge, with the potential to bring additional, much-needed treatment options to…
For #Media & #Investors: Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront.
So much of the power of science is realized through community—through the ways we share research, come together around tough scientific challenges, and work together to tackle diseases like cancers. Proud to have joined our @Novartis teams at ASCO, where we shared strong and…
It was great to sit down with the team at @YahooFinance to talk about some of the exciting news in oncology at @Novartis and what our renewed strategy means for our pipeline of innovative medicines. Thanks for having me, @juleshyman @AnjKhem @thebradsmith
“Over the past 10 years… we’ve completely refocused Novartis from being a broad conglomerate," @Novartis CEO @VasNarasimhan says. "We had seven divisions… now we’re just focusing on high-end innovative medicines..."
I want to encourage @Harvard alumni in my network to vote in the #Harvard elections before they close this week. I couldn’t be prouder my wife Srishti Gupta Narasimhan has been nominated for the Board of Overseers—a testament to her leadership and commitment to education. Voting…
I spent part of my early career in malaria clinics across Africa and continue to be passionate about creating a malaria-free world. As we marked #WorldMalariaDay this week, I wanted to share the history of this ancient scourge and perspectives for the way forward:…
Highlighted by a positive Phase 3 readout in early breast cancer, our pipeline momentum gives us confidence in our growth outlook. More on our Q1 results and the strong growth Novartis delivered to start 2023: bit.ly/3N6gy8O
With the strong Q1 results we shared today, I’m extremely proud of how Novartis has started 2023. Our strong start to the year and confidence in our growth drivers allow us to raise our full-year guidance.
Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance. #NovartisNews $NVS $NOVN #NVSQ123
The heart of our company is our science. Today’s news builds on our longstanding commitment to improving and extending the lives of breast cancer patients. I couldn’t be prouder of our teams working on this medicine.
Novartis announces topline data from a Phase III study of a CDK4/6 inhibitor in a broad population of people diagnosed with stage II and III HR+/HER2- early #BreastCancer #NovartisNews
About to go live #HBRat100. Looking forward to an energizing conversation about the future of business and @Novartis's important role in the next generation of health. Thanks for having me, @HarvardBiz
United States Trends
- 1. #AEWFullGear 38,1 B posts
- 2. $CUTO 5.633 posts
- 3. Auburn 9.282 posts
- 4. Kansas 36,8 B posts
- 5. Milroe 2.985 posts
- 6. Colorado 64,5 B posts
- 7. Notre Dame 20,4 B posts
- 8. Oklahoma 28,4 B posts
- 9. #BeatTheSnail N/A
- 10. Devin Neal 6.594 posts
- 11. Big 12 20 B posts
- 12. Bauer Sharp N/A
- 13. Ryan Williams N/A
- 14. Xavier Robinson N/A
- 15. Arizona State 9.640 posts
- 16. #NWSLChampionship 1.918 posts
- 17. #MostRequestedLive 19,9 B posts
- 18. Cam Coleman 1.233 posts
- 19. #LAMH 1.165 posts
- 20. Vandy 4.656 posts
Who to follow
-
Jay Bradner, M.D.
@jaybradner -
Novartis
@Novartis -
Novartis News
@NovartisNews -
Bristol Myers Squibb
@bmsnews -
Bruce Booth
@LifeSciVC -
John Carroll
@JohnCendpts -
Jeb Keiper
@JebKeiper -
Biotech Hangout
@BiotechCH -
Novartis US
@NovartisUS -
Frank S. David
@Frank_S_David -
Luke Timmerman
@ldtimmerman -
Novartis US Medical
@NovartisUSMed -
Michael Gilman
@michael_gilman -
Novartis Science
@NovartisScience -
John Maraganore 🇺🇦🇮🇱
@JMaraganore
Something went wrong.
Something went wrong.